Original Article
Brief Report
Nephrogenic Syndrome of Inappropriate Antidiuresis
N Engl J Med 2005; 352:1884-1890May 5, 2005
- Abstract
The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common cause of hyponatremia. We describe two infants whose clinical and laboratory evaluations were consistent with the presence of SIADH, yet who had undetectable arginine vasopressin (AVP) levels. We hypothesized that they had gain-of-function mutations in the V2 vasopressin receptor (V2R). DNA sequencing of each patient's V2R gene (AVPR2) identified missense mutations in both, with resultant changes in codon 137 from arginine to cysteine or leucine. These novel mutations cause constitutive activation of the receptor and are the likely cause of the patients' SIADH-like clinical picture, which we have termed “nephrogenic syndrome of inappropriate antidiuresis.”
Media in This Article
Figure 1
Nucleotide Sequence of the Wild-Type and Two Mutant AVPR2 Genes in the Affected Region (Panel A) and Diagram of V2R (Panel B).Figure 2
Basal Levels of cAMP Production in Cells Expressing Wild-Type and Mutant V2R.Article Activity
- Article
Fluid homeostasis depends on proper water intake, governed by an intact thirst mechanism, and on urinary excretion of free water, mediated by appropriate secretion of arginine vasopressin (AVP) (also known as antidiuretic hormone).1 AVP exerts its antidiuretic action by binding to the V2 vasopressin receptor (V2R), a G protein–coupled receptor, on the basolateral membrane of epithelial cells in the collecting duct of the kidney. Ligand binding activates the V2R, stimulating adenylate cyclase by means of Gs proteins. The resulting increase in intracellular cyclic AMP (cAMP) promotes shuttling of intracellular vesicles containing the water channel aquaporin-2 to the apical membrane of the collecting-duct cells, thereby increasing water permeability and inducing antidiuresis.
Clinical disorders of water balance are common, and alterations in many steps of this pathway have been described.1 Urinary concentrating defects associated with diabetes insipidus may result from a deficiency of AVP or from nephrogenic causes, such as X-linked, inactivating mutations in the V2R or autosomal recessive or autosomal dominant lesions in aquaporin-2.2 Conversely, the syndrome of inappropriate antidiuretic hormone secretion (SIADH) manifests as an inability to excrete a free water load, with inappropriately concentrated urine and resultant hyponatremia, hypo-osmolality, and natriuresis. SIADH occurs in the setting of euvolemia, without evidence of renal disease or thyroxine or cortisol deficiency. Though usually transient, SIADH may be chronic; it is often associated with drug use or a lesion in the central nervous system or lung. When the cardinal features of SIADH were defined by Bartter and Schwartz,3 AVP levels could not be measured. Subsequently, radioimmunoassays have revealed that SIADH is usually associated with measurably elevated serum levels of AVP.
We describe two unrelated male infants whose clinical presentation was consistent with the presence of chronic SIADH but who had undetectable AVP levels. We postulated that novel activating mutations of the V2R might account for their unique presentation. Evaluation revealed novel activating mutations of the V2R leading to what we term “nephrogenic syndrome of inappropriate antidiuresis” (NSIAD).
Case Reports
Patient 1 presented at 3 months of age with irritability, and Patient 2 presented at 2.5 months of age with two generalized seizures. Both children had had unremarkable early neonatal courses. Both were exclusively bottle-fed formula (7 mmol of sodium per liter). Both infants had mild systolic hypertension with otherwise normal physical examinations. Initial laboratory evaluations demonstrated hyponatremia with normal serum levels of potassium and bicarbonate (Table 1Table 1
Characteristics of the Two Patients.). Both children had serum hypo-osmolality with inappropriately elevated urinary osmolality and urinary sodium levels. Both had low blood urea nitrogen and low or low-normal serum creatinine levels, low or suppressed plasma renin activity, and normal aldosterone levels, indicating euvolemia. Serum cortisol, thyroid-function tests, and coagulation studies were all normal. Imaging studies of the head and chest were unremarkable, with the exception of a small pars intermedia cyst in Patient 2. Despite clinical and laboratory presentations consistent with the presence of SIADH, serum AVP levels were undetectable in both patients (Quest Diagnostics Nichols Institute). Both children were initially treated with fluid restriction, followed by the administration of an osmotic agent (urea), resulting in increased urinary output and normalization of the serum sodium level.Neither child had a family history of hyponatremia or of an SIADH-like syndrome. Both patients had no siblings. The mother of Patient 1, subsequently found to be heterozygous for an activating mutation of AVPR2 (see below), had normal simultaneous serum sodium levels (140 mmol per liter) and serum and urine osmolality (293 and 795 mOsm per kilogram of water, respectively).
The parents of the patients provided written informed consent for the publication of the case reports through a protocol approved by the institutional review board of the University of California at San Francisco.
Methods
Mutation Analysis
Genomic DNA from the two patients and their mothers was isolated from whole blood with the use of the Puregene Blood Kit (Gentra Systems). The entire coding region of the V2R gene, AVPR2, was amplified as described previously.4 The resulting amplicons were sequenced with multiple forward and reverse primers with the use of Big Dye (version 3.1) sequencing chemistry and an ABI Prism sequencer (model 3100, Applied Biosystems) according to the manufacturer's protocols. SeqScape software (Applied Biosystems) was used to assemble the sequence data and compare the results with the AVPR2 reference sequence (GenBank accession number NT 025965).
Construction of Vasopressin Expression Constructs
pCDNA3 (Invitrogen) was used as the control plasmid. Human wild-type V2R complementary DNA (cDNA),5 subcloned into pCDNA3, was used as a normal control and template for mutagenesis. Site-directed mutagenesis was performed with the use of a QuickChange II site-directed mutagenesis kit (Stratagene). Mutations were confirmed by direct sequencing.
Cell Culture and Transient Transfection
For functional studies, COS-7 cells were cultured in Dulbecco's modified Eagle's medium with 10 percent fetal-calf serum and antibiotics. Cells were plated in six-well plates (Falcon 3046, Becton Dickinson) at approximately 95 percent confluence 24 hours before transfection with the use of Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Each well received 3 μg of plasmid DNA and 500 ng of a cAMP-responsive luciferase reporter plasmid (pCREluc) containing 16 copies of the consensus cAMP response element.6 To control for transfection efficiency, cells were cotransfected with 50 ng of renilla luciferase reporter plasmid (pRL-CMV, Promega) per well. Cells were incubated at 37°C in 5 percent carbon dioxide for 24 hours after transfection and were then lysed and assayed for luciferase activity with the use of the Dual Luciferase Reporter Assay System (Promega), as described previously.7,8 Data are presented as mean (±SE) luciferase activity expressed in arbitrary units and adjusted for renilla luciferase activity in three experiments, each performed in triplicate. All five types of samples (pCDNA3 vector alone and vector with wild-type V2R, the R137C mutant, the R137L mutant, or the R137H mutant) were run simultaneously under the same conditions during each of the three experiments.
Results
Genomic DNA was isolated from both boys and their mothers, and the V2R gene, AVPR2, was sequenced directly. AVPR2 is X-linked, and therefore, paternal DNA is not informative. Each patient carried a mutation in codon 137 of AVPR2. In Patient 1, nucleotide 770 was mutated from cytosine to thymine, changing arginine to cysteine at codon 137 (R137C); in Patient 2, nucleotide 771 was mutated from guanine to thymine, changing arginine to leucine at codon 137 (R137L) (Figure 1AFigure 1
Nucleotide Sequence of the Wild-Type and Two Mutant AVPR2 Genes in the Affected Region (Panel A) and Diagram of V2R (Panel B).). Arginine 137 maps to the predicted second cytoplasmic loop, near the cytoplasmic boundary of the third transmembrane domain; this same amino acid is mutated to histidine (R137H) in a form of familial nephrogenic diabetes insipidus (Figure 1B). The mother of Patient 1 was heterozygous for the R137C mutation, whereas the mother of Patient 2 was homozygous for wild-type AVPR2, suggesting that Patient 2 had a spontaneous mutation.To evaluate the effect of these novel mutations on V2R function, we developed a functional assay for V2R. Production of cAMP has previously been used to assess many G protein–coupled receptors, including V2R9; we adopted our previous procedures8 to use with V2R. COS-7 cells transiently transfected with the vector alone, wild-type V2R, or the R137H nephrogenic diabetes insipidus mutant induced low levels of cAMP (Figure 2Figure 2
Basal Levels of cAMP Production in Cells Expressing Wild-Type and Mutant V2R.). However, basal levels of cAMP production in cells expressing V2R with the R137C mutation were four times the levels in cells expressing wild-type V2R (P=0.01), and cells expressing the R137L mutant had 7.5 times the level of activity of cells expressing wild-type V2R (P<0.004) (Figure 2). These results indicate that these novel mutations create a constitutively active V2R and provide an explanation for the hyponatremia with increased urinary osmolality in our patients. The condition in both patients is clinically similar to SIADH, despite the fact that AVP levels were undetectable.Discussion
G protein–coupled receptors constitute the largest gene family of receptors involved in signal transduction and are responsible for regulating many physiological processes.10 Many diseases are caused by mutations in G protein–coupled receptors.11,12 For some G protein–coupled receptors, a particular disease state has been ascribed to inactivating mutations that render the receptors unresponsive to ligand, whereas a converse condition has been linked to gain-of-function mutations, resulting in constitutive activation.
Although many different inactivating mutations of the X-linked V2R have been described that cause nephrogenic diabetes insipidus,2 to our knowledge, no naturally occurring activating mutations of the V2R have been reported previously. The two cases described here are characterized by chronic SIADH but with undetectable AVP levels, constituting a novel example of gain-of-function mutations caused by a hemizygous V2R mutation. In the light of these findings, we suggest referring to all SIADH-like conditions as syndromes of inappropriate antidiuresis (SIAD) and that these two case reports constitute a subtype, NSIAD. To our knowledge, these cases are the only reported examples in which mutations affecting the same amino acid cause two different genetic diseases: R137H causes nephrogenic diabetes insipidus, and R137L and R137C cause NSIAD (Figure 1B).
The mechanism by which these missense mutations constitutively activate the V2R requires further investigation. V2R, a class 1b G protein–coupled receptor,12,13 exists in the plasma membrane in equilibrium with inactive and active conformations.10 The binding of ligand shifts the equilibrium to the active state, permitting coupling with intracellular G proteins and activation of intracellular effectors. With activation, V2R is desensitized through phosphorylation by specific G protein–coupled receptor kinases. Subsequent recruitment of β arrestin to the phosphorylated receptor terminates the signal by blocking further interaction with G proteins and also initiates receptor internalization through its ability to bind clathrin and other endocytic adapters.14
By comparison with other class 1 G protein–coupled receptors, the highly conserved motif of aspartic acid, arginine, and tyrosine or histidine (DRY/H) in V2R at the junction of the third transmembrane domain and second intracellular loop appears to be critical for receptor function. The arginine residue in the DRY/H motif appears to be invariant, though the aspartic acid and tyrosine may be replaced by other amino acids without altering the function (e.g., from aspartic acid to glutamic acid).15 The arginine residue in the DRY/H motif corresponds to R137, the site of the inactivating R137H mutation in nephrogenic diabetes insipidus and the activating R137C and R137L mutations in NSIAD. The R137H mutant behaves as a constitutively desensitized receptor, since it is phosphorylated, binds to β arrestin (thereby blocking its ability to activate G proteins), and is sequestered in intracellular vesicles.16
Constitutively activated mutant G protein–coupled receptors have also been created by altering this DRY/H motif17 — for example, through in vitro mutation of aspartate to alanine at codon 136 in the V2R.18 The NSIAD mutations found in this domain may stabilize the receptor in an active conformation, activating G proteins and downstream signaling events in the absence of ligand. In theory, such a gain of function could also affect many other aspects of V2R biology, including phosphorylation, internalization, down-regulation, and recycling to the cell membrane.
The effects of the constitutive activation of V2R may not be limited to the kidney. V2R is also expressed in endothelial cells, where it appears to mediate vasodilation after the administration of the vasopressin analogue desmopressin19,20 and to mediate the rise in circulating levels of von Willebrand factor and tissue plasminogen activator.21 We thought that these responses, which are absent in patients with nephrogenic diabetes insipidus,22 might be constitutively activated in our patients with NSIAD. However, we found no clinical or laboratory evidence of coagulopathy in either patient (Table 1).
The frequency of NSIAD is not known, but it may not be rare. Previous studies of patients with SIADH have noted variable patterns of AVP secretion, particularly in response to water loading and water restriction.23 As many as 10 to 20 percent of affected patients have AVP levels at or below the limits of detection by radioimmunoassay. Thus, some of these patients may in fact have NSIAD due to V2R-activating mutations. Such patients would probably have clinical presentations similar to those in our patients, although the severity and clinical course may depend on the nature of the mutation. Patients with NSIAD would be expected to have low AVP levels. However, since the AVP assay is not optimized to identify low values, we recommend sequencing the V2R gene to identify specific mutations before the diagnosis of NSIAD is finalized. Other patients may be identified who have the NSIAD phenotype but without V2R mutations, suggesting the presence of additional defects in this signaling cascade. One such possibility would be an activating mutation in aquaporin-2.
Treatment of NSIAD poses a challenge. Water restriction improved serum sodium levels and osmolality in both infants but limited calorie intake in these formula-fed infants. Agents that act downstream from the V2R, such as demeclocycline or lithium, might antagonize the constitutively activated receptors, but they have potentially limiting adverse effects. AVP antagonists are under clinical development but would probably be ineffective, given the ligand-independent nature of the lesion.24 Ideally, one might be able to use an inverse agonist that would suppress receptor activity in the absence of agonist; two potential nonpeptide V2R inverse agonists have been studied in vitro.18 In the absence of a definitive therapy, we have successfully treated our patients with urea to induce an osmotic diuresis.25 This approach has occasionally been used for the treatment of chronic SIADH in adults.26
Study of the V2R has been important for understanding the physiology of water balance and has served as a prototype for G protein–coupled receptor biology. Further characterization of NSIAD may offer additional insights into fluid homeostasis and clinical disease, as well as expand our understanding of G protein–coupled receptor signaling.
Supported in part by a training grant (T32DK07161, to Drs. Feldman and Huang) and a grant (M01RR01271, to the Pediatric Clinical Research Center) from the National Institutes of Health.
Dr. Rosenthal reports having received grant support and speaking honoraria from Pfizer and having served on an advisory board for Tercica and Pfizer. Dr. Vargas reports having received grant support from Wyeth and Janssen. Dr. Lustig reports having received lecture fees from Novo Nordisk and grant support from Novartis. Dr. Mathias reports having equity interest in AstraZeneca, Pfizer, Merck, and SIRNA Therapeutics; receiving grant support from Satellite Healthcare and Genentech; and receiving speaking honoraria from Shire. Dr. Fenwick is employed by Quest Diagnostics, owns stock in the company, and developed the clinical assay used for sequencing AVPR2 in this study.
Drs. Feldman and Rosenthal contributed equally to this article.
We are indebted to Ian Ocrant and Kamer Tezcan for referring the patients; to Mariel Birnbaumer (National Institute of Environmental Health Sciences, Division of Intramural Research) for sharing the V2R cDNA; to Christian Vaisse (University of California at San Francisco) for the cAMP-responsive luciferase reporter plasmid; to Mark von Zastrow (University of California at San Francisco), Jon Nakamoto (Quest Diagnostics), and Hillel Gitelman for thoughtful discussions and review of the manuscript; and to Izabella Damm (University of California at San Francisco) for technical support.
Source Information
From the Department of Pediatrics, Divisions of Endocrinology (B.J.F., S.M.R., E.A.H., R.H.L., W.L.M., S.E.G.) and Nephrology (M.M.-A., R.S.M., A.A.P.), and the Department of Psychiatry (G.A.V.), University of California at San Francisco, San Francisco; and Quest Diagnostics Nichols Institute, San Juan Capistrano, Calif. (R.G.F.).
Address reprint requests to Dr. Gitelman at the University of California at San Francisco, Division of Pediatric Endocrinology, 513 Parnassus Ave., Rm. S679, Box 0434, San Francisco, CA 94143, or at sgitelma@peds.ucsf.edu.
- References
References
1
Robertson GL . Antidiuretic hormone: normal and disordered function. Endocrinol Metab Clin North Am 2001;30:671-694
CrossRef | Web of Science | Medline2
Morello JP ,Bichet DG . Nephrogenic diabetes insipidus. Annu Rev Physiol 2001;63:607-630
CrossRef | Web of Science | Medline3
Bartter FC ,Schwartz WB . The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1967;42:790-806
CrossRef | Web of Science | Medline4
Bichet DG ,Arthus MF ,Lonergan M , et al. X-linked nephrogenic diabetes insipidus mutations in North America and the Hopewell hypothesis. J Clin Invest 1993;92:1262-1268
CrossRef | Web of Science | Medline5
Birnbaumer M ,Gilbert S ,Rosenthal W . An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system. Mol Endocrinol 1994;8:886-894
CrossRef | Web of Science | Medline6
Vaisse C ,Clement K ,Durand E ,Hercberg S ,Guy-Grand B ,Froguel P . Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000;106:253-262
CrossRef | Web of Science | Medline7
Stables J ,Scott S ,Brown S , et al. Development of a dual glow-signal firefly and Renilla luciferase assay reagent for the analysis of G-protein coupled receptor signalling. J Recept Signal Transduct Res 1999;19:395-410
CrossRef | Web of Science | Medline8
Fluck CE ,Martens JW ,Conte FA ,Miller WL . Clinical, genetic, and functional characterization of adrenocorticotropin receptor mutations using a novel receptor assay. J Clin Endocrinol Metab 2002;87:4318-4323
CrossRef | Web of Science | Medline9
Rosenthal W ,Antaramian A ,Gilbert S ,Birnbaumer M . Nephrogenic diabetes insipidus: a V2 vasopressin receptor unable to stimulate adenylyl cyclase. J Biol Chem 1993;268:13030-13033
Web of Science | Medline10
Pierce KL ,Premont RT ,Lefkowitz RJ . Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002;3:639-650
CrossRef | Web of Science | Medline11
Spiegel AM ,Weinstein LS . Inherited diseases involving G proteins and G protein-coupled receptors. Annu Rev Med 2004;55:27-39
CrossRef | Web of Science | Medline12
Seifert R ,Wenzel-Seifert K . Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 2002;366:381-416
CrossRef | Web of Science | Medline13
Bockaert J ,Pin JP . Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J 1999;18:1723-1729
CrossRef | Web of Science | Medline14
Luttrell LM ,Lefkowitz RJ . The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002;115:455-465
Web of Science | Medline15
Probst WC ,Snyder LA ,Schuster DI ,Brosius J ,Sealfon SC . Sequence alignment of the G-protein coupled receptor superfamily. DNA Cell Biol 1992;11:1-20
CrossRef | Web of Science | Medline16
Barak LS ,Oakley RH ,Laporte SA ,Caron MG . Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci U S A 2001;98:93-98
CrossRef | Web of Science | Medline17
Parnot C ,Miserey-Lenkei S ,Bardin S ,Corvol P ,Clauser E . Lessons from constitutively active mutants of G protein-coupled receptors. Trends Endocrinol Metab 2002;13:336-343
CrossRef | Web of Science | Medline18
Morin D ,Cotte N ,Balestre MN , et al. The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities. FEBS Lett 1998;441:470-475
CrossRef | Web of Science | Medline19
Hirsch AT ,Dzau VJ ,Majzoub JA ,Creager MA . Vasopressin-mediated forearm vasodilation in normal humans: evidence for a vascular vasopressin V2 receptor. J Clin Invest 1989;84:418-426
CrossRef | Web of Science | Medline20
Kaufmann JE ,Iezzi M ,Vischer UM . Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling. J Thromb Haemost 2003;1:821-828
CrossRef | Web of Science | Medline21
Mannucci PM ,Ruggeri ZM ,Pareti FI ,Capitanio A . 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's diseases. Lancet 1977;1:869-872
CrossRef | Web of Science | Medline22
Bichet DG ,Razi M ,Lonergan M , et al. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 1988;318:881-887
Full Text | Web of Science | Medline23
Zerbe R ,Stropes L ,Robertson G . Vasopressin function in the syndrome of inappropriate antidiuresis. Annu Rev Med 1980;31:315-327
CrossRef | Web of Science | Medline24
Verbalis JG . Vasopressin V2 receptor antagonists. J Mol Endocrinol 2002;29:1-9
CrossRef | Web of Science | Medline25
Huang EA ,Geller DH ,Gitelman SE . The use of oral urea in the treatment of chronic syndrome of inappropriate antidiuretic hormone secretion (SIADH) in children. Pediatr Res 2004;55:161A-161A abstract.
Web of Science26
Decaux G ,Prospert F ,Penninckx R ,Namias B ,Soupart A . 5-Year treatment of the chronic syndrome of inappropriate secretion of ADH with oral urea. Nephron 1993;63:468-470
CrossRef | Medline
- Citing Articles (50)
Citing Articles
1
Robert P. Millar, Claire L. Newton, Antonia K. Roseweir. 2012. Neuroendocrine GPCR Signaling. , 21-53.
CrossRef2
Detlef Bockenhauer, Michael D. Penney, David Hampton, William van't Hoff, Ambrose Gullett, Sankar Sailesh, Daniel G. Bichet. (2011) A Family With Hyponatremia and the Nephrogenic Syndrome of Inappropriate Antidiuresis. American Journal of Kidney Diseases
CrossRef3
Bertrand L. Jaber, Leena Almarzouqi, Lea Borgi, Victor F. Seabra, Ethan M. Balk, Nicolaos E. Madias. (2011) Short-term Efficacy and Safety of Vasopressin Receptor Antagonists for Treatment of Hyponatremia. The American Journal of Medicine 124:10, 977.e1-977.e9
CrossRef4
Sayali A. Ranadive, Stephen M. Rosenthal. (2011) Pediatric Disorders of Water Balance. Pediatric Clinics of North America 58:5, 1271-1280
CrossRef5
Gaëtan Bellot, Robert Pascal, Christiane Mendre, Serge Urbach, Bernard Mouillac, Hélène Déméné. (2011) Expression, purification and NMR characterization of the cyclic recombinant form of the third intracellular loop of the vasopressin type 2 receptor. Protein Expression and Purification 78:2, 131-138
CrossRef6
Frederic Vandergheynst, Olivier Pradier, Ingrid Beukinga, Anne Kornreich, Gilbert Vassart, Guy Decaux. (2011) Lack of responsiveness to 1-desamino-d arginin vasopressin (desmopressin) in male patients with nephrogenic syndrome of inappropriate antidiuresis: from bench to bedside. European Journal of Clinical Investigationno-no
CrossRef7
Muriel Babey, Peter Kopp, Gary L. Robertson. (2011) Familial forms of diabetes insipidus: clinical and molecular characteristics. Nature Reviews Endocrinology
CrossRef8
Gilbert Vassart, Sabine Costagliola. (2011) G protein-coupled receptors: mutations and endocrine diseases. Nature Reviews Endocrinology 7:6, 362-372
CrossRef9
Ewout J. Hoorn. (2011) Renal tubular disorders: From proteins to patients. Clinical Biochemistry 44:7, 503-504
CrossRef10
C. OVERGAARD-STEENSEN. (2011) Initial approach to the hyponatremic patient. Acta Anaesthesiologica Scandinavica 55:2, 139-148
CrossRef11
Pasquale Esposito, Giovanni Piotti, Stefania Bianzina, Yehuda Malul, Antonio Dal Canton. (2011) The Syndrome of Inappropriate Antidiuresis: Pathophysiology, Clinical Management and New Therapeutic Options. Nephron Clinical Practice 119:1, c62-c73
CrossRef12
Elizabeth F. Daher, Natália A. Rocha, Michelle J.C. Oliveira, Luiz F.L.G. Franco, Jobson L. Oliveira, Geraldo B. Silva Junior, Krasnalhia Lívia S. Abreu, Guilherme A.L. Henn, Alice M.C. Martins, Alexandre B. Libório. (2011) Renal Function Improvement with Pentavalent Antimonial Agents in Patients with Visceral Leishmaniasis. American Journal of Nephrology 33:4, 332-336
CrossRef13
Daniel G. Bichet. 2011. The Posterior Pituitary. , 261-299.
CrossRef14
E. N. Levtchenko, L. A. H. Monnens. (2010) Nephrogenic syndrome of inappropriate antidiuresis. Nephrology Dialysis Transplantation 25:9, 2839-2843
CrossRef15
2010. Suggested Readings. , 575-581.
CrossRef16
Sayali A. Ranadive, Stephen M. Rosenthal. (2009) Pediatric Disorders of Water Balance. Endocrinology & Metabolism Clinics of North America 38:4, 663-672
CrossRef17
R. Zietse, N. van der Lubbe, E. J. Hoorn. (2009) Current and future treatment options in SIADH. NDT Plus 2:Supplement 3, iii12-iii19
CrossRef18
Sayali A. Ranadive, Baran Ersoy, Helene Favre, Clement C. Cheung, Stephen M. Rosenthal, Walter L. Miller, Christian Vaisse. (2009) Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clinical Endocrinology 71:3, 388-393
CrossRef19
W. Tian, Y. Fu, A. Garcia-Elias, J. M. Fernandez-Fernandez, R. Vicente, P. L. Kramer, R. F. Klein, R. Hitzemann, E. S. Orwoll, B. Wilmot, S. McWeeney, M. A. Valverde, D. M. Cohen. (2009) A loss-of-function nonsynonymous polymorphism in the osmoregulatory TRPV4 gene is associated with human hyponatremia. Proceedings of the National Academy of Sciences 106:33, 14034-14039
CrossRef20
David R. Repaske. 2009. Disorders of Water Balance. , 343-373.
CrossRef21
Vimal Chadha, Uri S. Alon. (2009) Hereditary Renal Tubular Disorders. Seminars in Nephrology 29:4, 399-411
CrossRef22
2009. Pituitary Gland Testing. , 59-123.
CrossRef23
David B. Mount. (2009) Hyponatremia: Introduction. Seminars in Nephrology 29:3, 175-177
CrossRef24
Guy Decaux. (2009) The Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH). Seminars in Nephrology 29:3, 239-256
CrossRef25
P. Gross, T. Marczewski, K. Herbrig. (2009) The vaptans ante portas: a status report. Nephrology Dialysis Transplantation 24:5, 1371-1373
CrossRef26
YoonHi Cho, Stephen Gitelman, Stephen Rosenthal, Geoffrey Ambler. (2009) Long-Term Outcomes in a Family with Nephrogenic Syndrome of Inappropriate Antidiuresis. International Journal of Pediatric Endocrinology 2009:1, 431527
CrossRef27
Yoon Hi Cho, Stephen Gitelman, Stephen Rosenthal, Geoffrey Ambler. (2009) Long-Term Outcomes in a Family with Nephrogenic Syndrome of Inappropriate Antidiuresis. International Journal of Pediatric Endocrinology 2009, 1-4
CrossRef28
Michael L. Moritz, Juan Carlos Ayus. 2009. Diabetes Insipidus and SIADH. , 261-286.
CrossRef29
Tomas Berl, Robert W. Schrier. 2009. Vasopressin Antagonists in Physiology and Disease. , 249-260.
CrossRef30
Maria Antonietta Marcialis, Valeria Faà, Vassilios Fanos, Melania Puddu, Maria Cristina Pintus, Antonio Cao, Maria Cristina Rosatelli. (2008) Neonatal onset of nephrogenic syndrome of inappropriate antidiuresis. Pediatric Nephrology 23:12, 2267-2271
CrossRef31
Ferenc Laczi. (2008) A hyponatraemiás állapotok etiológiája, diagnosztikája és terápiája. Orvosi Hetilap 149:29, 1347-1354
CrossRef32
Lowell Clark, Catherine Preissig, Mark R. Rigby, Frank Bowyer. (2008) Endocrine Issues in the Pediatric Intensive Care Unit. Pediatric Clinics of North America 55:3, 805-833
CrossRef33
F. Vandergheynst, G. Decaux. (2008) Lack of elevation of urinary albumin excretion among patients with chronic syndromes of inappropriate antidiuresis. Nephrology Dialysis Transplantation 23:7, 2399-2401
CrossRef34
Guy Decaux, Alain Soupart, Gilbert Vassart. (2008) Non-peptide arginine-vasopressin antagonists: the vaptans. The Lancet 371:9624, 1624-1632
CrossRef35
Rajesh Krishnan, Lorraine Eley, John A. Sayer. (2008) Urinary Concentration Defects and Mechanisms Underlying Nephronophthisis. Kidney and Blood Pressure Research 31:3, 152-162
CrossRef36
LOUIS J. MUGLIA, JOSEPH A. MAJZOUB. 2008. Disorders of the Posterior Pituitary. , 335-373.
CrossRef37
ALAN M. RICE, SCOTT A. RIVKEES. 2008. Receptor Transduction of Hormone Action. , 26-73.
CrossRef38
Nicolaos E. Madias. (2007) Effects of Tolvaptan, an Oral Vasopressin V2 Receptor Antagonist, in Hyponatremia. American Journal of Kidney Diseases 50:2, 184-187
CrossRef39
Ellison, David H., Berl, Tomas, . (2007) The Syndrome of Inappropriate Antidiuresis. New England Journal of Medicine 356:20, 2064-2072
Full Text40
Arthur J. Siegel, Joseph G. Verbalis, Stephen Clement, Jack H. Mendelson, Nancy K. Mello, Marvin Adner, Terry Shirey, Julie Glowacki, Elizabeth Lee-Lewandrowski, Kent B. Lewandrowski. (2007) Hyponatremia in Marathon Runners due to Inappropriate Arginine Vasopressin Secretion. The American Journal of Medicine 120:5, 461.e11-461.e17
CrossRef41
David Francisco Bes, Hernán Mendilaharzu, Raymond G. Fenwick, Elvira Arrizurieta. (2007) Hyponatremia resulting from Arginine Vasopressin Receptor 2 gene mutation. Pediatric Nephrology 22:3, 463-466
CrossRef42
Stephen M. Rosenthal, Stephen E. Gitelman, Gabriel A. Vargas, Brian J. Feldman. (2007) Gain-of-Function Mutations in the V2 Vasopressin Receptor. Hormone Research 67:1, 121-125
CrossRef43
Andrea G Lania, Giovanna Mantovani, Anna Spada. (2006) Mechanisms of Disease: mutations of G proteins and G-protein-coupled receptors in endocrine diseases. Nature Clinical Practice Endocrinology & Metabolism 2:12, 681-693
CrossRef44
Angela Schulz, Holger Römpler, Doreen Mitschke, Doreen Thor, Nicole Schliebe, Thomas Hermsdorf, Rainer Strotmann, Katrin Sangkuhl, Torsten Schöneberg. (2006) Molecular basis and clinical features of nephrogenic diabetes insipidus. Expert Review of Endocrinology & Metabolism 1:6, 727-741
CrossRef45
W.L. Boson, T. Della Manna, D. Damiani, D.M. Miranda, M.R. Gadelha, B. Liberman, H. Correa, M.A. Romano-Silva, E. Friedman, F.F. Silva, P.A. Ribeiro, L. De Marco. (2006) Novel Vasopressin Type 2 ( AVPR2 ) Gene Mutations in Brazilian Nephrogenic Diabetes Insipidus Patients. Genetic Testing 10:3, 157-162
CrossRef46
Rachel K Crowley, C J Thompson. (2006) Syndrome of inappropriate antidiuresis. Expert Review of Endocrinology & Metabolism 1:4, 537-547
CrossRef47
Rebecca M. Reynolds, Jonathan R. Seckl. (2005) Hyponatraemia for the clinical endocrinologist. Clinical Endocrinology 63:4, 366-374
CrossRef48
Charles Strom. (2005) In Defense of Commercial Laboratories. Genetics in Medicine 7:8, 590
CrossRef49
(2005) Nephrogenic Syndrome of Inappropriate Antidiuresis. New England Journal of Medicine 353:5, 529-530
Full Text50
Knoers, Nine V.A.M., . (2005) Hyperactive Vasopressin Receptors and Disturbed Water Homeostasis. New England Journal of Medicine 352:18, 1847-1850
Full Text
- Letters
